# CYB004 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cyb004

> CYB004, sponsored by Helus Pharma Inc. (HELP): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CYB004 |
| Codes | CYB004 |
| Sponsor | Helus Pharma Inc. (HELP) https://sec-api.dev/companies/help/catalysts |
| Indications | [moderate to severe gad](https://sec-api.dev/indications/moderate-to-severe-gad), [generalized anxiety disorder](https://sec-api.dev/indications/generalized-anxiety-disorder) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### January 8, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1.
- First seen 2024-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000043): "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary deuterated DMT molecules, CYB004 and SPL028." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000007): "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary deuterated DMT molecules, CYB004 and SPL028." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000007/cybin-mdaxq1x26.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000001): "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary deuterated DMT molecules, CYB004 and SPL028." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000001/cybin-mdaxq3x25xdecember31.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-24-000018): "On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary deuterated DMT molecules, CYB004 and SPL028." https://www.sec.gov/Archives/edgar/data/1833141/000183314124000018/cybin-mdaxq2x25xseptember3.htm

### March 15, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: moderate to severe GAD.
- First seen 2024-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000043): "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000007): "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000007/cybin-mdaxq1x26.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000001): "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000001/cybin-mdaxq3x25xdecember31.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-24-000018): "On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD." https://www.sec.gov/Archives/edgar/data/1833141/000183314124000018/cybin-mdaxq2x25xseptember3.htm

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2024-11-13, last confirmed 2025-02-11.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001391): "- Topline efficacy data from Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder ("GAD") expected in Q1 2025 -" https://www.sec.gov/Archives/edgar/data/1833141/000162828025001391/a01-13x2025cybnyearxendprf.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001391): "oThe Phase 2 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with GAD, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed oThe Phase 2 study is being conducted at sites in the U.S., with topline safety and efficacy results expected in Q1 2025" https://www.sec.gov/Archives/edgar/data/1833141/000162828025001391/a01-13x2025cybnyearxendprf.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001391): "Forward-looking statements in this news release include statements regarding the Company's plans to report Phase 2 topline results for CYB004 in Q1 2025; timing of the initiation and ability of the Company to enroll participants for the PARADIGM program; the potential for BTD to accelerate drug development timelines; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions." https://www.sec.gov/Archives/edgar/data/1833141/000162828025001391/a01-13x2025cybnyearxendprf.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000001): "Forward-looking statements in this news release include statements regarding the Company's plans to report Phase 2 topline results for CYB004 in H1 2025" https://www.sec.gov/Archives/edgar/data/1833141/000183314125000001/cybn-q32025earningsandnewa.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-24-000018): "•Dosing is underway in a Phase 2 study in generalized anxiety disorder with topline safety and efficacy results expected in Q1 2025." https://www.sec.gov/Archives/edgar/data/1833141/000183314124000018/q22024-cyb003phase3initiat.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000001): "•The Phase 2 study is being conducted at sites in the U.S., with topline safety and efficacy results expected in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000001/cybn-q32025earningsandnewa.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000001): "•Dosing is underway and topline safety and efficacy readout from Phase 2 GAD study is expected in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000001/cybn-q32025earningsandnewa.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Generalized Anxiety Disorder.
- First seen 2025-09-09, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000021): "We are proud of this work to date, as well as the robust patent protection in support of our CYB004 program, and we look forward to sharing topline data in the first quarter of 2026."" https://www.sec.gov/Archives/edgar/data/1833141/000183314125000021/a09-2025cyb004enrollmentco.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000021): "Forward-looking statements in this news release include statements regarding the Company's plans to share CYB004 topline data in the first quarter of 2026; potential for CYB004 to provide convenient intramuscular dosing and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000021/a09-2025cyb004enrollmentco.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000025): "Topline data expected Q1 2026 -" https://www.sec.gov/Archives/edgar/data/1833141/000183314125000025/cybncorpupdatesept232025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000021): "- Reaffirms top-line data guidance for Q1 2026 -" https://www.sec.gov/Archives/edgar/data/1833141/000183314125000021/a09-2025cyb004enrollmentco.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000043): "Forward-looking statements in this news release include statements regarding the Company's expectation to advance towards its upcoming data readouts and beyond; the Company's expectations to report topline data from Phase 2 study evaluating CYB004 in Q1 2026; enroll 220 patients across 45 U.S. clinical sites in APPROACH study; initiate enrollment in EMBRACE™ Study in Q4 2025 targeting 330 participants with moderate to severe MDD; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybn-q22026earningspr.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000025): "Forward-looking statements in this news release include statements regarding the Company's expectation to release topline Phase 2 data for CYB004 in the first quarter of 2026; expectation to enroll 220 participants at 45 clinical sites across the United States for the APPROACH study; release of topline data from APPROACH study in the fourth quarter of 2026; initiation of EMBRACE study in the fourth quarter of 2025; expectation to enroll 330 participants in the EMBRACE study; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000025/cybncorpupdatesept232025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000021): "TORONTO, CANADA - September 8, 2025 - Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced completion of enrollment in its Phase 2 study evaluating CYB004, a proprietary deuterated dimethyltryptamine ("DMT") program, for the treatment of Generalized Anxiety Disorder ("GAD") and reaffirms top line data guidance expected in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000021/a09-2025cyb004enrollmentco.htm

## Same indication

- [CYB003](https://sec-api.dev/pdufa/cyb003) (HELP)
- [HLP004](https://sec-api.dev/pdufa/hlp004) (HELP)
- [GlyphAgo (SPT-320)](https://sec-api.dev/pdufa/spt-320) (PTCHF)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cyb004.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CYB004 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cyb004

```bibtex
@misc{secapidev_pdufa_cyb004_20261116,
  title        = {CYB004 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cyb004}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cyb004_20261116","title":"CYB004 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cyb004","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
